Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells

Background Mesenchymal stem/stromal cells (MSC) accumulate and reside in tumor sites.Methods Taking advantage of this feature in anticancer therapy, immortalized murine MSC (iMSC) were genetically altered to produce chemokine (C-C motif) ligand 19 (iMSC/CCL19), which attracts dendritic cells (DC) an...

Full description

Saved in:
Bibliographic Details
Main Authors: Mitsuo Oshimura, Yuichi Iida, Rintaro Yoshikawa, Akihiko Murata, Hitoshi Kotani, Yasuhiro Kazuki, Yumi Matsuzaki, Mamoru Harada
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000582.full
Tags: Add Tag
No Tags, Be the first to tag this record!